Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.44 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501801 | 0.79 | POLB (0.33) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL26501684 | 0.78 | SLC40A1 (0.36) | RAB9ACYP1A2CYP2D6CYP2C9GRM1 | |
| SCHEMBL10084285 | 0.77 | ELOVL1 (0.64) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL26501703 | 0.76 | MAPT (0.39) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5477855 | 0.76 | SMN1; SMN2 (0.52) | CYP1A2CYP2D6CYP2C9GRM1SLC12A2 | |
| SCHEMBL26501700 | 0.74 | PTPN1 (0.40) | RAB9ANPC1POLBSMN1; SMN2MEN1 | |
| SCHEMBL26501545 | 0.73 | SMN1; SMN2 (0.51) | RAB9ANPC1POLBSMN1; SMN2MEN1 | |
| SCHEMBL12597453 | 0.72 | CYP1A2 (0.48) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12190585 | 0.71 | L3MBTL1 (0.57) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL26501659 | 0.70 | SLC40A1 (0.34) | RAB9APOLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | RAB9A 3971/4885NPC1 189/4885CYP1A2 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.